Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM6ENSJ)

Drug Name
Tralokinumab Drug Info
Synonyms CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca
Indication
Disease Entry ICD 11 Status REF
Atopic dermatitis EA80 Approved [1]
Ulcerative colitis DD71 Phase 3 [2]
Asthma CA23 Phase 1/2 [3]
Cross-matching ID
TTD Drug ID
DM6ENSJ

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-13 (IL13) TT0GVCH IL13_HUMAN Inhibitor [4]
Interleukin 13 receptor alpha-2 (IL13RA2) TTMPZ7V I13R2_HUMAN Modulator [5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-13 (IL13) DTT IL13 3.036 2.945 1.848 3.776
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Atopic dermatitis
ICD Disease Classification EA80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 13 receptor alpha-2 (IL13RA2) DTT IL13RA2 4.40E-01 2.46 1
Interleukin 13 receptor alpha-2 (IL13RA2) DTT IL13RA2 5.77E-05 4.14 2.11
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761180.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8001).
3 ClinicalTrials.gov (NCT02085473) A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Tralokinumab When Delivered at Different Flow Rates to Healthy Volunteers
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.Am J Respir Cell Mol Biol.2014 May;50(5):985-94.